SOX9 is required for kidney fibrosis and activates NAV3 to drive renal myofibroblast function. (2021)
Attributed to:
MICA: The North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1126/scisignal.abb4282
PubMed Identifier: 33653921
Publication URI: http://europepmc.org/abstract/MED/33653921
Type: Journal Article/Review
Volume: 14
Parent Publication: Science signaling
Issue: 672
ISSN: 1945-0877